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cartilage, synovial membrane, and connective
tissue is elevated in rats with collagen induced
arthritis
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Background: Rheumatoid arthritis is a disease affecting the extracellular matrix of especially synovial joints. The
thickness of the synovial membrane increases and surrounding tissue degrades, leading to altered collagen balance
in the tissues. In this study, we investigated the altered tissue balance of cartilage, synovial membrane, and
connective tissue in collagen induced arthritis (CIA) in rats.
Methods: Six newly developed ELISAs quantifying MMP-derived collagen degradation (C1M, C2M, and C3M) and
formation (P1NP, P2NP, and P3NP) was used to detect cartilage turnover in rats with CIA. Moreover, CTX-II was used
to detect alternative type II collagen degradation and as control of the model. 10 Lewis rats were injected with
porcrine type II collagen twice with a 7 day interval and 10 rats was injected with 0.05 M acetic acid as control. The
experiment ran for 26 days.
Results: A significant increase in the degradation of type I, II, and III collagen (C1M, C2M, and C3M, respectively)
was detected on day 22 (P = 0.0068, P = 0.0068, P < 0.0001, respectively), whereas no significant difference in
formation (P1NP, P2NP, and P3NP) was detected at any time point (P=0.22, P=0.53, P=0.53, respectively). The CTX-II
level increased strongly from disease onset and onwards.
Conclusion: A nearly total separation between diseased and control animals was detected with C3M, making it a
good diagnostic marker. The balance of type I, II, and III collagen was significantly altered with CIA in rats, with
favour of degradation of the investigated collagens. This indicates unbalanced turnover of the surrounding tissues
of the synovial joints, leading to increased pain and degeneration of the synovial joints.
Keywords: Collagen balance, Rheumatoid arthritis, Matrix metalloproteinase, Synovial membrane, Cartilage,
Connective tissueBackground
Rheumatoid arthritis (RA) is a chronic inflammatory di-
sease, which primarily affects the extra-cellular matrix
(ECM) of the synovial joints [1]. The exact etiology of
the disease is still unknown, but several factors such as
gender [2], genetics [3,4] and antigens [1] are thought to
be involved. The extensive inflammation of the synovial
membrane (i.e. synovitis) and other joint tissues induces* Correspondence: aso@nordicbioscience.com
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reproduction in any medium, provided the orsecretion of proteolytic enzymes leading to degradation
of cartilage and elevated bone turnover [5-7].
The synovial membrane is divided into two separate
layers, an intimate layer of cells embedded in ECM and a
sub-intimae layer of loose connective tissue [8,9]. The first
layer consists of two types of cells, fibroblast-like synovio-
cytes and macrophages. These cells form a capsule enclo-
sing the joint, containing type I and III collagen [9,10]. In
healthy individuals this layers is approximately 1–4 cells
thick, whereas it can be up to 12 cells thick in individuals
with RA [1,8]. The increased amount of cells results in
increased concentrations of degradative enzymes, such asl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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which are released into the synovial fluid, leading to
increased degradation and formation of the surrounding
ECM of cartilage, connective tissue, and the synovial
membrane itself [11-13]. It is well known that MMP-1, -3,
-9, and −13 is upregulated with RA [13-15]. These MMP’s
are important proteolytic enzymes in ECM breakdown as
MMP-1 degrades type I, II and III collagen, MMP-3
degrades, amongst other ECM proteins, type III collagen
and the proteoglycans of cartilage, MMP-9 degrades type
IV and V collagens, and MMP-13 degrades type I, II, and
III collagen, however type II collagen more efficiently than
type I and III collagen.
The protein fragments derived from the proteolytic
enzyme cleavage, called neo-epitopes, are potentially
released from the tissues and may enter into the circula-
tion and thereby serve as biochemical markers indicating
the degree of tissue destruction. There are already se-
veral commercial biochemical markers availably utilizing
neo-epitopes; CTX-I [16], PIIANP [17], COMP [18], and
ICTP [19].
In this study we used newly developed biochemical mar-
kers based on neo-epitopes of type I, II, and III collagen
degradation (C1M [20], C2M [21], C3M [22]) and forma-
tion (P1NP [23], P2NP(unpublished), P3NP(unpublished))
to describe the turnover of cartilage, synovial membrane,
and connective tissue. The degradation markers are all
derived from cleavage with RA related MMP’s and espe-
cially C3M have shown to be increased with increasing fi-
brosis [24-28] and Ankylosing Spondylitis [29]. The
formation markers are all measures of the N-terminal
pro-collagen, which are also believed to be MMP derived.
Moreover, to assess in more detail the degradation of car-
tilage and to control that the CIA model was working, the
well-known CTX-II was used [30].
The aim of this study was to investigate the effect of
autoimmunity by collagen induced arthritis (CIA) on
type I, II, and III collagen turnover in rats utilizing the
newly developed biomarker assays C1M, C2M, C3M,
P1NP, P2NP, and P3NP, as well as CTX-II, before arth-
ritis occur and at a late stage of arthritis.Methods
Reagents
If not stated chemicals and reagents were purchased
from Sigma-Aldrich (Copenhagen, Denmark) or VWR
(Herlev, Denmark). The ELISA plate, pre-coated with
streptavidin (nunc clear 96 well-plates), were purchased
from Roche Diagnostics (cat.: 11940279, Mannheum,
Germany). All ELISA plates were analyzed with the
ELISA reader from Molecular Devices, SpectraMax M,
(CA, USA). Rats were purchased from Charles River
(Charles River, Germany). Antibodies were produced atNordic Bioscience, Beijing. ELISA coating peptides was
purchased from American Peptide Company.
Collagen induced arthritis in rats
CIA was induced in 10, 7 week old, female Lewis rats by
immunizing with 450 μl 2 mg/ml porcine type II colla-
gen dissolved in 0.05 M acetic acid and emulsified 1:1 in
Incomplete Freunds Adjuvant on day 0 and 7, as
described earlier [30]. 10 Lewis rats only injected with
0.05 M acetic acid was used as control. Every day, start-
ing from day 8, rats were examined for visual signs of
disease, defined as macroscopic evidence of increase in
paw size, determined paw score. A score from 0–4 was
given depending on the swelling; 0: No evidence of ery-
thema and swelling, 1: Erythema and mild swelling con-
fined to the tarsals or ankle joint, 2: Erythema and mild
swelling extending from the ankle to the tarsals, 3: Ery-
thema and moderate swelling extending from the ankle
to the metatarsal joints, 4: Erythema and severe swelling
encompass the ankle, foot, and digits or ankylosis of the
limb. Rats reaching a paw score of 10 were sacrificed,
due to too great pain. Moreover, paw volume was mea-
sured. Paw volume is a widely used method to detect
disease in the CIA model [31,32]. Paw volume increases
due to inflammation, which is accompanied by intersti-
tial oedema. We used a simple and accurate method to
determine paw volume described before [32], with minor
changes. Briefly, a 200 ml beaker with Mill-Q water was
placed on a sensitive digital weight (sensitivity: 0.01 g).
The rat’s paws were, one by one, lowered into the water.
The sum of difference in weight from baseline for the
paws was determined as the arbitrary number of paw
size. The animal experiment protocol was approved by
the local animal Ethics committee at Nordic Bioscience
Beijing. The ethical approval number is NBB-AM-R/
2009-01.
On day 16 all CIA rats were diseased, determined by
paw score. The rats were sacrificed on day 26, besides if
there were extensive paw swelling, determined by paw
score, or a too great weight loss (>10%), then rats was ter-
minated earlier. Serum samples were collected throughout
the experiment from overnight fasted animals.
Quantification of collagens
Degradation of type I collagen
The newly developed C1M ELISA detects degraded type
I collagen by MMP-2, -9, and −13 [20]. The ELISA is
based a monoclonal antibody (mAb) recognising the
fragment GSPGKDGVRG at position 764 in the mature
type I collagen. Briefly, 100 μl biotinylated coater peptide
was added to a streptavitin coated plate. This was incu-
bated at 20°C for 30 min, with agitation. Next, the plate
was washed 5 times in washing buffer. Twenty μl sample
or standard together with 100 μl HRP-labelled antibody
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1 hour with agitation, followed by washing 5 times in
washing buffer. One-hundred μl 3,3’,5,5’-tetramethylben-
zidine (TMB) was added and incubated for 15 min. in
the dark at 20°C with agitation. Lastly, 100 μl stop buffer
(0.1% H2SO4) was added, before reading the plate at
540/590 nm on an ELISA reader, SpectraMax M. Tech-
nical data on C1M is listed in Table 1.
Formation of type I collagen
The newly, previously described P1NP ELISA detects
formation of type I collagen [23]. The assay is specific of
a fragment (PEEYVSPDAEVIG) in the N-terminal pro-
peptide of type I collagen. Briefly, 100 μl biotinylated
coater peptide was added to a streptavidin coated plate
and was incubated at 4°C for 30 min, with agitation.
Next, the plate was washed 5 times in washing buffer.
Twenty μl sample or standard together with 100 μl
HRP-labelled antibody was added to the plate. This was
incubated at 4°C for 1 hour with agitation, followed by
washing 5 times in washing buffer. One-hundred μl
TMB was added and incubated for 15 min. in the dark
at 20°C with agitation. Lastly, 100 μl stop buffer (0.1%
H2SO4) was added, before reading the plate at 540/
590 nm on an ELISA reader, SpectraMax M. Technical
data on P1NP is listed in Table 1.
Degradation of type II collagen
The novel, previously described, C2M (aka. CIIM)
ELISA [21] detects a MMP-degradation fragment
(RDGAAG) at position 1053 in the mature type II colla-
gen. Moreover, the commercial available ELISA, CTX-II,
detects degradation of type II collagen. This assay was
run accordingly to the manufactures protocol. The
protocol for C2M was briefly; 100 μl biotinylated coater
peptide was added to a streptavidin coated plate and was
incubated at 20°C for 30 min, with agitation. Next, the
plate was washed 5 times in washing buffer. Twenty μl
sample or standard together with 100 μl HRP-labelled
antibody was added to the plate. This was incubated atTable 1 Overview of the technical specifications of the ELISA’
Assay name Target Specificity of
C1M [20] Degradation of type I collagen Neo-epitope g
MMP-2, 9, and
C2M [21] Degradation of type II collagen Neo-epitope g
several MMP
C3M [22] Degradation of type III collagen Neo-epitope g
MMP-9
P1NP [23] Formation of type I collagen N-terminal pro
P2NP (unpublished) Formation of type II collagen N-terminal pro
P3NP (unpublished) Formation of type III collagen N-terminal pro4°C for overnight with agitation, followed by washing 5
times in washing buffer. One-hundred μl TMB was
added and incubated for 15 min. in the dark at 20°C
with agitation. Lastly, 100 μl stop buffer (0.1% H2SO4)
was added, before reading the plate at 540/590 nm on
an ELISA reader, SpectraMax M. Technical data on
C2M is listed in Table 1.
Formation of type II collagen
The novel P2NP ELISA detects the N-terminal pro-
peptide of type II collagen (unpublished). A mAb was
raised against the neo-epitope and an ELISA was made
with the neo-epitope (biotinylated) as coater in an
ELISA plate coated with streptavidin. The neo-epitope
was used as standard [1000 ng/ml-0 ng/ml], to get a
quantitative ELISA. Briefly, 100 μl biotinylated coater
peptide was added to a streptavidin coated plate and was
incubated at 20°C for 30 min, with agitation. Next, the
plate was washed 5 times in washing buffer. Twenty μl
sample or standard together with 100 μl HRP-labelled
antibody was added to the plate. This was incubated at
4°C overnight with agitation, followed by washing 5
times in washing buffer. One-hundred μl TMB was
added and incubated for 15 min. in the dark at 20°C with
agitation. Lastly, 100 μl stop buffer (0.1% H2SO4) was
added, before reading the plate at 540/590 nm on an
ELISA reader, SpectraMax M. Technical data on P2NP is
listed in Table 1.
Degradation of type III collagen
The C3M ELISA is a newly developed ELISA, which is spe-
cific of aMMP-9 degradation fragment (GGPGQPGTEGNK)
of mature type III collagen [22]. Shortly, 100 μl biotinylated
coater peptide was added to a streptavidin coated plate and
was incubated at 20°C for 30 min, with agitation. Next, the
plate was washed 5 times in washing buffer. Twenty μl sample
or standard together with 100 μl HRP-labelled antibody was
added to the plate. This was incubated at 20°C for 1 hour with
agitation, followed by washing 5 times in washing buffer.
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(0.1% H2SO4) was added, before reading the plate at 540/
590 nm on an ELISA reader, SpectraMax M. Technical data
on C3M is listed in Table 1.
Formation of type III collagen
The formation of type III collagen was quantified with the
newly developed competitive P3NP assay (unpublished).
The assay is specific of the fragment (PTGPQNYSP),
which is a fragment in the N-terminal pro-peptide of type
III collagen. A mAb was raised against the fragment and
an ELISA was developed with the fragment (biotinylated)
as coater in an ELISA plate coated with streptavidin. To
quantify the formation level, the peptide was used a stand-
ard in the range [1000 ng/ml-0 ng/ml]. Briefly, 100 μl bio-
tinylated coater peptide was added to a streptavidin
coated plate and was incubated at 20°C for 30 min, with
agitation. Next, the plate was washed 5 times in washing
buffer. Twenty μl sample or standard together with 100 μl
HRP-labelled antibody was added to the plate. This was
incubated at 4°C overnight with agitation, followed by
washing 5 times in washing buffer. One-hundred μl TMB
was added and incubated for 15 min. in the dark at 20°C
with agitation. Lastly, 100 μl stop buffer (0.1% H2SO4) was
added, before reading the plate at 540/590 nm on an
ELISA reader, SpectraMax M. Technical data on P3NP is
listed in Table 1.
Statistics
All values are presented as mean ± standard error of
mean (SEM) with 10 replications in each of the groups.
Significant difference between mean (day 7 and 22) and
the day of first immunization (baseline) was determined
using the non-parametric Mann–Whitney t-test. Differ-
ences were considered statistically significant if P < 0.05
and significant level as: * = P < 0.05, ** = P < 0.01, and ***:
P < 0.001. The turnover of collagen was calculated by
taken the ratio of formation compared to degradation.
Results
Animal health and disease incidence
The earliest signs of disease in the CIA group were
observed on day 14, measured by increase in paw vol-
ume (Figure 1A). By day 16 all immunized rats showed
sign of disease (Figure 1C) and this time point was
defined as disease onset. Paw volume increased in the
diseased rat throughout the experiment, whereas no in-
crease in paw volume was detected in the control group
(Figure 1A). In addition, paw score was assessed and a
significant difference between the groups was detected
from day 15 and until termination of the experiment
(Figure 1B). Three animals in the diseased group were
sacrificed before the end of the study, due to a paw score
higher than 10. The swelling of the paws was detected inthe hind paws one to two days before signs of swelling
were detected in the front paws. At the late stage, the ac-
tivity of diseased rats were affected by the swelling, as
most of the time, they were not active.
Figure 1D depicts the weight of the animals. The mean
weight of the control group followed the normal weight
gain for growing rats, with an increase of approximately
12% during the 3 weeks of the experiment. The mean
weight of the CIA rat increased more rapidly until dis-
ease onset (day 16), whereafter the weight decreased sig-
nificantly (p < 0.001) compared to the control group.Tissue balance of connective tissue, cartilage, and
synovial membrane
The tissue balance of connective tissue was assessed by
measurements of degradation and formation of type I colla-
gen. The level of all biochemical markers of collagen is
listed in Table 2. A 51.2% (P=0.0068) increase in type I col-
lagen degradation (C1M) was detected in serum from dis-
eased animals on a late time point (day 22) compared to
baseline level (Figure 2B). No difference in degradation of
type I collagen was found between the groups before dis-
ease onset (day 7, Figure 2A). A decrease in formation of
type I collagen (P1NP) compared to baseline level were
detected in both treated and control animals during the ex-
periment, but with no significance between the groups
(Figure 2C, D). This imbalanced amount of degradation
and formation, led to an overall significant increase in turn-
over (i.e. ratio between degradation and formation) of type
I collagen on day 22 of 169% (P=0.0052) in the diseased
animals (Figure 2F). No significant difference was detected
at the early time point in the control or diseased group
(Figure 2E).
Type II collagen was used to determine the tissue bal-
ance of cartilage, as type II collagen is the main collagen
of cartilage and it is not abundant in any other tissue.
Degradation of type II collagen was measured by two
different assays, utilizing two different neo-epitopes; the
novel C2M ELISA [21] and the well-known CTX-II
ELISA [33]. Both C2M and CTX-II showed significantly
increased degradation in the diseased animals compared
to control at the late time point, 31.9% (P = 0.0068) and
10963% (P = 0.0004), respectively (Figure 3B, D). How-
ever, CTX-II already showed increased degradation by
more than 100% at disease onset in the treated animals
compare to control (data not shown). No change in type
II collagen degradation was detected before disease
onset (Figure 3A, C). Furthermore, there was no signifi-
cant difference between the formation of type II collagen
(P2NP) in diseased animals compared to baseline or
control (Figure 3E, F). Only at the late time point a sig-
nificant increase (11765%, P = 0.0004) of turnover of type
II collagen was detected with CTX-II (Figure 3J).

















































































Figure 1 The percentage increase in paw volume (A), paw score (B), percentage disease incidence (C), and percent weight changes (D)
observed post 1st immunization. The CIA group (squares, n = 10) and control animals (circles, n = 10) were compared by Mann–Whitney t-test.
All statistical analyses were calculated based on baseline corrected values. Data are shown as mean± SEM and significance levels as *: P < 0.05,
**: P < 0.01, ***: P < 0.001.
Table 2 Biochemical markers measured in serum on day 7
and 22 compared to baseline
Time point Control CIA P-value
C1M Day 7 9.939± 7.963 15.63 ± 9.461 0.6038
Day 22 9.283± 7.216 51.2 ± 8.947 0.0068 **
C2M Day 7 5.376± 10.15 12.39 ± 11.54 0.5490
Day 22 −7.593 ± 7.610 31.92 ± 10.51 0.0068 **
CTX-II Day 7 −38.89 ± 41.61 −81.54 ± 6.355 0.7487
Day 22 −87.71 ± 12.29 10963± 5236 0.0004 ***
C3M Day 7 −1.609 ± 4.95 4.312± 8.117 0.6608
Day 22 0.4491 ± 3.92 39.73 ± 5.447 <0.0001 ***
P1NP Day 7 −14.72 ± 9.157 −19.59 ± 13.53 0.4002
Day 22 −20.67 ± 5.433 ,35.59 ± 7.097 0.2176
P2NP Day 7 2.327± 13.29 −4.001 ± 5.772 0.8633
Day 22 3.346± 11.57 −4.766 ± 9.643 0.8534
P3NP Day 7 −1.829 ± 3.588 −8.746 ± 2.936 0.3562
Day 22 2.334± 2.849 6.045± 2.790 0.5288
The CIA (n = 10) and control groups (n = 10) were compared by Man-Whitney
t-test on both days. All statistical analyses were calculated based on baseline
corrected values. Data are shown as mean ± SEM and significance levels as
*: P < 0.05, **: P < 0.01, ***: P < 0.001.
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synovial membrane, was determined by quantification of
degradation and formation of type III collagen, the main
collagen in the synovial membrane. The degradation of
type III collagen (C3M) was increased with 39.7%
(P < 0.0001) at the late time point in the diseased group
compared to control (Figure 4B), but no change was
detected at the early time point (Figure 4A). There was
no significant difference in formation of type III collagen
(P3NP) between the groups at the early or late time
point (Figure 4C, D). However, a tendency towards ele-
vated formation was detected in the diseased animals
compared to baseline on the late time point. Overall, an
elevated, but not significant, amount (17.4%, P = 0.24) of
type III collagen turnover was detected in the diseased
rats at the early time point (Figure 4E) and a significant
increase in turnover was detected at the late time point
(32.4%, P < 0.0001, Figure 4F).Discussion
Synovitis is the main characteristic of RA, however, the
effect on the tissues involved of the increasing amount
of proteolytic enzymes released into the synovial fluid
due to the increase in synovial cells have not been stud-














































































































































































































































Figure 2 Biomarkers of type I collagen turnover on day 7 and 22 corrected to baseline. A, B: Type I collagen degradation detected with
C1M. Range of measurement was [55.4-116.7]. C, D: Formation of type I collagen detected with P1NP. Range of measurement was [398.0-8603.1].
E, F: Calculations of type I collagen turnover. Range of measurement was [0.009-0.1]. The CIA group (black, n = 10) and control animals (white,
n = 10) were compared by Mann–Whitney t-test. All statistical analysis was calculated based on baseline corrected values. Data are shown as
mean± SEM and significance levels as *: P < 0.05, **: P < 0.01, ***: P < 0.001.
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derived from cleavage with proteolytic enzymes, specific-
ally MMP’s. An increase of degradation of type I, II, and
III collagens was found, reflecting an elevated level of
turnover of the collagens after disease onset. No signifi-
cant difference in the formation of the collagens was
detected between controls and diseased rats at any time
point. In summary, the tissue balance of cartilage, syn-
ovial membrane, and connective tissue was disturbed.
The ELISA used to quantify type I collagen MMP-
driven turnover (C1M [20], P1NP [23]) is not bone spe-
cific as conventional ELISAs of type I collagen, but the
neo-epitope of the ELISA derives from connectivetissues. C1M have earlier been found to significantly in-
crease in ankylosing spondylitis patients compared to
gender and age matched controls [29]. As there was no
significant difference in the formation of type I collagen
between the groups or compared to baseline in our
study, an overall increase in type I collagen turnover was
observed. This indicates an altered balance of connective
tissue in the CIA rats towards degradation. Type I colla-
gen is the most abundant collagen in vertebrates and is
found in scar tissue, skeleton, synovial membrane, skin,
tendons, ligaments, artery, etc. Many macromolecules,
such as integrins, fibronectin, and decorin bind to type I








































































































































































































































































































































































































































Figure 3 (See legend on next page.)
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(See figure on previous page.)
Figure 3 Biomarkers of type II collagen turnover on day 7 and 22 corrected to baseline. A, B: Type II collagen degradation detected with
C2M. Range of measurement was [0.3-1.2]. C, D: Type II degradation detected with CTX-II. Range of measurement was [0.2-2132.7]. E+ F.
Formation of type II collagen detected with P2NP. Range of measurement was [167.3-877.5]. G, H: Calculations of type II collagen turnover with
C2M. Range of measurement was [0.0005-0.006]. I + J: Calculation of type II collagen turnover with CTX-II. Range of measurement was [0.3-72.0].
The CIA group (black, n = 10) and control animals (white, n = 10) were compared by Mann Whitney t-test. All statistical analyses were calculated
based on baseline corrected values. Data are shown as mean± SEM and significance levels as *: P < 0.05, **: P < 0.01, ***: P < 0.001.
Siebuhr et al. Journal of Translational Medicine 2012, 10:195 Page 8 of 11
http://www.translational-medicine.com/content/10/1/195ECM protein [34-36]. Therefore, the increased degrad-
ation of type I collagen in this experiment could reflect
many metabolic processes. It could be that the skeleton
and tendons weakens, due to decreased movement be-
cause of pain, or the increase in fibroblast in the synovial
membrane increase the level of MMP’s increasing the
degradation of type I collagen in the surrounding bone
and synovial membrane. What exactly the degradation
of type I collagen reflects in this experiment is still to be
determined.
Type II collagen is the most abundant collagen in car-
tilage and CTX-II have in many studies been used to
quantify cartilage degradation [30,37,38]. CTX-II has
been shown to increase in RA patients receiving treat-
ment (Cyclosporine, Methotrexate, and/or Steroid) com-
pared to baseline. However, not even after four years of
treatment a positive change in cartilage formation was
detected, meaning that cartilage balance is compromised
even at diagnosis of RA [37]. In the same study
Christensen et al. showed that the CTX-II level was cor-
related to RA activity, demonstrating that the CTX-II
level is coupled to synovitis activity [37]. In another
study, a reduction in CTX-II level was found after three
months in RA patients receiving treatment (prednisol-
one, Methotrexate, sulfasalazine alone or in combin-
ation) [39]. This result conflict with the earlier described
study by Christensen et al. [37], where no positive effect
of treatment was detected on cartilage. Together, these
results could indicate that the right treatment could help
the right patient group. However, there is no evidence
for this theory yet.
A 250% increase in cartilage degradation quantified by
CTX-II in serum was detected at a late time point in dis-
eased rats in a pre-clinical study of CIA rats. However,
an even greater increase (400%) in degradation was
detected between the diseased rats and controls, when
quantifying CTX-II in paw extracts [30]. However, alone
CTX-II only reflects a part of the mechanisms of cartil-
age breakdown, suggesting that a panel of biomarkers of
type II collagen degradation are to be used to get a
broader understanding of mechanisms of cartilage
breakdown. In this study we used both C2M and CTX-
II, which showed relatively different levels of degrad-
ation, however the same profile. Both markers of type II
collagen was used, not only to get a broader understand-
ing of collagen breakdown, but also because CTX-II wasused a control of the CIA model working, as CTX-II
have been described in the model previously [30]. C2M
is detecting a neo-epitope of type II collagen derived
from MMP-cleavage, which is specific of articular cartil-
age [21], where the neo-epitope in CTX-II is also derived
from MMP-cleavage, but it is present during both bone
sclerosis and growth plate remodelling [40]. In this ex-
periment the CTX-II fragment was detected to a much
higher extend (343 times) than the C2M fragment. This
may partly reflect the release of several different MMPs
from synovial fibroblasts in the inflamed synovial mem-
brane, which could account for the difference in degrad-
ation level of cartilage reflected in this study. A
difference in cartilage breakdown, when comparing two
biomarkers, has previously been shown with CTX-II and
Helix-II [41]. In this study Charni-Ben et al. suggested
using various biomarkers reflecting the same metabolic
process concurrently to increase the knowledge about
the metabolic process. This is true in the case of basal
science, but when applied to clinical science, measuring
several biomarkers reflecting one metabolic process will
be overestimating. In the clinic, a panel of biomarkers
reflecting different metabolisms in a given disease gives
a broader understanding of the specific case and a better
tool to diagnose. Moreover, as both biomarkers of cartil-
age degradation showed the same profile of cartilage
breakdown in our experiment, one biomarker of cartil-
age degradation is adequate to estimate the state of car-
tilage balance. As CTX-II is only detectable in human
urine and not human serum and C2M is detectable in
both human urine and serum, C2M is a better candidate
for use in the clinics, as blood samples are already used
to detect C-Reactive Protein and Rheumatoid factor and
urine samples will therefore not be needed.
The compromised balance of connective tissue and cartil-
age turnover is, as stated earlier, a result of the thickened
synovial membrane. As RA is an inflammatory disease of
the synovial joint, a prognostic RA biomarker panel must
include biomarkers to detect the state of the inflamed syn-
ovial membrane. This could potentially be used to detect
RA in an early stage, i.e. before joint degradation. In this
study, we used the turnover of type III collagen, as a marker
of the synovial membrane. As the synovial membrane
thickness, due to fibrogenesis, an increase in P3NP and no
change in C3M were expected. However, a significant




















































































































































































































































Figure 4 Biomarkers of type III collagen turnover on day 7 and 22 corrected to baseline. A, B: Type III collagen degradation detected with
C3M. Range of measurement was [2.6-35.5]. C, D: Formation of type III collagen detected with P3NP. Range of measurement was [13.9-71.5]. E, F:
Calculations of type III collagen turnover Range of measurement was [0.1-0.6]. The CIA group (black, n = 10) and control animals (white, n = 10)
were compared by Mann-Whitneyt-test. All statistical analyses were calculated based on baseline corrected values. Data are shown as
mean± SEM and significance levels as *: P < 0.05, **: P < 0.01, ***: P < 0.001.
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in formation was found between CIA and control rats in
this experiment, though a tendency towards increased
P3NP in diseased rats was detected at the late time point.
This suggests inhibited fibrogenesis in the diseased rats
after disease onset and therefore not an increase of synovial
membrane thickness. However, the N-terminal propeptide
of type III collagen, on which P3NP is based, is not always
cleaved of before fibrillation [42]. Therefore, this quantifica-
tion of formation of type III collagen may be an underesti-
mation and misleading. Moreover, it is very likely that C3M
derives from other tissues and not exclusively from the syn-
ovial membrane. As the synovial joints swells great quicklyin the CIA model, an increase in type III collagen formation
(P3NP) was expected, which would correlate to synovial
membrane thickness. However, this seems not to be the
case.
Type III collagen degradation and formation separately
have in several studies been used to detect fibrogenesis
[24-28], however this study is the first to combine the
biomarkers and investigate tissue balance. In three dif-
ferent fibrosis models (two of liver and one of skin), type
III collagen degradation was measured with the C3M
ELISA assay. A significantly increase in C3M was
detected even after a short disease period in rats com-
pared to control rats [24-26]. However, P3NP is also
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increased. Myllylä et al. [43] found that P3NP was
increased in RA patients compared to controls and
Hakala et al. [44] even showed that P3NP was increased
in RA patients compared to osteoarthritis, psoriasis arth-
ritis, ankylosing spondylitis, and systemic lupus erythe-
matosus patients. Other groups have further enhanced
the knowledge that P3NP increases with fibrosis [27,28].
To our knowledge P3NP has not been measured along
with degradation markers of type III collagen in any
murine or human trials, thereby investigating fibrogen-
esis. We show that fibrogenesis of the synovial mem-
brane is inhibited in CIA rats. As especially C3M has
shown to be a possible diagnostic marker of fibrogenesis
in rat [24-26] and in Ankylosing Spondylitis patients
[29], an investigation if C3M could be an efficacy marker
for RA could be interesting. We propose to treat CIA
animals with MTX or another RA related drug, to inves-
tigate if the level of C3M decreases with treatment. Type
III collagen degradation will by itself not be specific of
RA, as this has also shown to be elevated in ankylosing
spondylitis patients. However, the right combination of
collagen biomarkers could be RA specific.
The diagnosis of RA is today based on imaging, self-
reported symptoms, and biochemical markers. However,
all of these biomarkers and symptoms are only applicable
on late stage disease. Therefore, a biomarker panel of early
diagnosis of RA is warranted, as this will increase the
chances of treatment, maybe even cure. It has been
showed that cartilage collagen regeneration is compro-
mised at a very early stage of RA and that this is not pri-
marily inflammation driven [37], increasing the evidence
that articular cartilage degradation is a possible early RA
biomarker. CTX-II could be one of these early non-
invasive biomarkers as CTX-II has been shown to predict
joint damage at 4 and 12 weeks in human trials [38]. How-
ever, as C2M is an articular cartilage specific biochemical
marker, C2M is a better candidate than CTX-II in an early
non-invasive biomarker panel of RA, but more studies
confirming it as an early marker is needed. In a measure-
ment of multiple surface proteins (a biomarker panel),
Fueldner et al. showed a better discrimination of RA and
controls, than when only determining one surface protein
[45]. This further increases the evidence of a biomarker
panel to be better diagnostic or prognostic than single bio-
markers [46]. Moreover, as the pathology of RA involved
several cell types, it is reasonable to detect the activation
state of more than one cell type.
In this experiment the weight of the rats in the CIA
groups was significantly increased before disease onset
(day 9). This could be due to water accumulation in the
tissues. After disease onset the weight of the diseased rats
decrease compared to control rats. This weight loss at the
late time point could be because of a decrease in bone andmuscle mass, due to reduced activity in the diseased rats.
As three rats were sacrificed before experiment termin-
ation and the decreased activity of the rats, we propose to
use another model of RA, to increase consistency and ani-
mal number at experiment termination.
Conclusions
In summary, we found increased turnover of type I, II,
and III collagen, indicating an altered balance of these
collagens in RA. The profile of the tissue balances indi-
cates that cartilage, synovial membrane, and connective
tissue are important events in RA. The novel C3M bio-
marker could discriminate between diseased and con-
trols, indicating this as a promising biomarker of
synovitis. We speculate that a combination of these bio-
logical relevant collagen turnover markers might be uti-
lised in a biomarker panel as diagnostic and prognostic
markers of RA.
Abbreviations
C1M: MMP degraded type I collagen; C2M: MMP degraded type II collagen;
C3M: MMP degraded type III collagen; CIA: Collagen induced arthritis; CTX-
II: C-terminal crosslinked telopeptide type II collagen; ELISA: Enzyme-linked
immunosorbent assay; P1NP: N-terminal neo-epitope of type I procollagen;
P2NP: N-terminal neo-epitope of type II procollagen; P3NP: N-terminal neo-
epitope of type III procollagen; RA: Rheumatoid arthritis; TBM: 3,3’,5,5-
tetramethylbenzidine.
Competing interests
Morten Karsdal is stock holder of Nordic Bioscience.
Authors’ contributions
ASS and AC B-J have designed the experiment. JW, JY and ZQ performed
the animal experiment. ASS measured the biochemical markers and did the
data analysis. Lastly AC B-J and MK did proofreading. All authors read and
approved the final manuscript prior to submission and re-submission.
Author details
1Nordic Bioscience, Herlev, Denmark. 2Nordic Bioscience, Beijing, China.
3Nordic Bioscience, Beijing, China. 4Nordic Bioscience, Beijing, China.
Received: 18 June 2012 Accepted: 17 September 2012
Published: 20 September 2012
References
1. Buch M, Emery P: The aetiology and pathogenesis of Rheumatoid
arthritis. Hospital Parmacist 2002, Ref Type: In Press.
2. Brennan P, Silman A: Why the gender difference in susceptibility to
rheumatoid arthritis? Ann Rheum Dis 1995, 54:694–695.
3. Macgregor AJ, et al: Characterizing the quantitative genetic contribution
to rheumatoid arthritis using data from twins. Arthritis Rheum 2000,
43:30–37.
4. Deighton CM, Wentzel J, Cavanagh G, Roberts DF, Walker DJ: Contribution of
inherited factors to rheumatoid arthritis. Ann Rheum Dis 1992, 51:182–185.
5. Rousseau JC, et al: Patients with rheumatoid arthritis have an altered
circulatory aggrecan profile. BMC Musculoskelet Disord 2008, 9:74.
6. Keyszer G, et al: Circulating levels of matrix metalloproteinases MMP-3
and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-
1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity
of rheumatoid arthritis versus other surrogate markers. J Rheumatol 1999,
26(2):251–258.
7. Mamehara A, et al: Serum matrix metalloproteinase-3 as predictor of joint
destruction in rheumatoid arthritis, treated with non-biological disease
modifying anti-rheumatic drugs. Kobe J Med Sci 2010, 56:E98–E107.
8. Smith MD: The normal synovium. Open Rheumatol J 2011, 5:100–106.
Siebuhr et al. Journal of Translational Medicine 2012, 10:195 Page 11 of 11
http://www.translational-medicine.com/content/10/1/1959. Eyre DR, Muir H: Type III collagen: A major constituent of rheumatoid and
normal human synovial membrane. Connect Tissue Res 1975, 4:11–16.
10. Lovell CR, Nicholls AC, Jayson MI, Bailey AJ: Changes in the collagen of
synovial membrane in rheumatoid arthritis and effect of D-penicillamine.
Clin Sci Mol Med 1978, 55:31–40.
11. Weiss JB, et al: Occurrence of type III collagen in inflamed synovial
membranes: a comparison between non rheumatoid, rheumatoid, and
normal synovial collagens. Biochem Biophys Res Commun 1975, 65:907–912.
12. Konttinen YT, et al: Analysis of 16 different matrix metalloproteinases
(MMP-1 to MMP-20) in the synovial membrane: different profiles in
trauma and rheumatoid arthritis. Ann Rheum Dis 1999, 58:691–697.
13. Kim KS, et al: Expression levels and association of gelatinases MMP-2 and
MMP-9 and collagenases MMP-1 and MMP-13 with VEGF in synovial
fluid of patients with arthritis. Rheumatol Int 2011, 31:543–547.
14. Pap T, et al: Differential expression pattern of membrane-type matrix
metalloproteinases in rheumatoid arthritis. Arthritis Rheum 2000, 43:1226–1232.
15. Lee EG, et al: Ethyl acetate fraction from Cudrania tricuspidata inhibits IL-
1beta-induced rheumatoid synovial fibroblast proliferation and MMPs,
COX-2 and PGE2 production. Biol Res 2010, 43:225–231.
16. Bonde M, et al: Measurement of bone degradation products in serum
using antibodies reactive with an isomerized form of an 8 amino acid
sequence of the C-telopeptide of type I collagen. J Bone Miner Res 1997,
12:1028–1034.
17. Rousseau JC, et al: Serum levels of type IIA procollagen amino terminal
propeptide (PIIANP) are decreased in patients with knee osteoarthritis
and rheumatoid arthritis. Osteoarthritis Cartilage 2004, 12(6):440–7.
18. Smith RK, Heinegard D: Cartilage oligomeric matrix protein (COMP) levels
in digital sheath synovial fluid and serum with tendon injury. Equine Vet J
2000, 32:52–58.
19. Melkko J, Niemi S, Risteli L, Risteli J: Radioimmunoassay of the
carboxyterminal propeptide of human type I procollagen. Clin Chem
1990, 36:1328–1332.
20. Leeming D, et al: A novel marker for assessment of liver matrix
remodeling: an enzyme-linked immunosorbent assay (ELISA) detecting a
MMP generated type I collagen neo-epitope (C1M). Biomarkers 2011,
16:616–628.
21. Bay-Jensen AC, et al: Enzyme-linked immunosorbent assay (ELISAs) for
metalloproteinase derived type II collagen neoepitope, CIIM–increased
serum CIIM in subjects with severe radiographic osteoarthritis. Clin
Biochem 2011, 44:423–429.
22. Barascuk N, et al: A novel assay for extracellular matrix remodeling
associated with liver fibrosis: An enzyme-linked immunosorbent assay
(ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III
collagen. Clin Biochem 2010, 43:899–904.
23. Leeming DJ, et al: Enzyme-linked immunosorbent serum assays
(ELISAs) for rat and human N-terminal pro-peptide of collagen type I
(PINP)–assessment of corresponding epitopes. Clin Biochem 2010,
43:1249–1256.
24. Vassiliadis E, et al: Measurement of CO3-610, a Potential Liver Biomarker
Derived from Matrix Metalloproteinase-9 Degradation of Collagen Type
III, in a Rat Model of Reversible Carbon-Tetrachloride-Induced Fibrosis.
Biomark Insights 2011, 6:49–58.
25. Veidal SS, et al: Matrix metalloproteinase-9-mediated type III collagen
degradation as a novel serological biochemical marker for liver
fibrogenesis. Liver Int 2010, 30:1293–1304.
26. Vassiliadis E, et al: Measurement of matrix metalloproteinase 9-mediated
collagen type III degradation fragment as a marker of skin fibrosis. BMC
Dermatol 2011, 11:6.
27. Lin DY, Chu CM, Sheen IS, Liaw YF: Serum carboxy terminal propeptide of
type I procollagen to amino terminal propeptide of type III procollagen
ratio is a better indicator than each single propeptide and 7S domain
type IV collagen for progressive fibrogenesis in chronic viral liver
diseases. Dig Dis Sci 1995, 40:21–27.
28. Ulrich D, Noah EM, Burchardt ER, Atkins D, Pallua N: Serum concentration
of amino-terminal propeptide of type III procollagen (PIIINP) as a
prognostic marker for skin fibrosis after scar correction in burned
patients. Burns 2002, 28:766–771.
29. Bay-Jensen AC, et al: Ankylosing spondylitis is characterized by an
increased turnover of several different metalloproteinase-derived
collagen species: a cross-sectional study. Rheumatol Int 2011.30. Nielsen RH, Christiansen C, Stolina M, Karsdal MA: Oestrogen exhibits type
II collagen protective effects and attenuates collagen-induced arthritis in
rats. Clin Exp Immunol 2008, 152:21–27.
31. Bolon B, et al: Rodent preclinical models for developing novel
antiarthritic molecules: comparative biology and preferred methods for
evaluating efficacy. J Biomed Biotechnol 2011, 2011:569068.
32. Fereidoni M, Ahmadiani A, Semnanian S, Javan M: An accurate and simple
method for measurement of paw edema. J Pharmacol Toxicol Methods
2000, 43:11–14.
33. Immunodiagnostic Systems Inc. Method; 2012. Ref Type: Electronic Citation.
34. Trojanowska M, LeRoy EC, Eckes B, Krieg T: Pathogenesis of fibrosis: type 1
collagen and the skin. J Mol Med (Berl) 1998, 76:266–274.
35. Jokinen J, et al: Integrin-mediated cell adhesion to type I collagen fibrils.
J Biol Chem 2004, 279:31956–31963.
36. Dzamba BJ, Wu H, Jaenisch R, Peters DM: Fibronectin binding site in type I
collagen regulates fibronectin fibril formation. J Cell Biol 1993, 121:1165–1172.
37. Christensen AF, et al: Uncoupling of collagen II metabolism in newly
diagnosed, untreated rheumatoid arthritis is linked to inflammation and
antibodies against cyclic citrullinated peptides. J Rheumatol 2010,
37:1113–1120.
38. Karsdal MA, et al: Biochemical markers of ongoing joint damage in
rheumatoid arthritis–current and future applications, limitations and
opportunities. Arthritis Res Ther 2011, 13:215.
39. Landewe R, et al: Markers for type II collagen breakdown predict the
effect of disease-modifying treatment on long-term radiographic
progression in patients with rheumatoid arthritis. Arthritis Rheum 2004,
50:1390–1399.
40. Bay-Jensen AC, et al: Biochemical markers of type II collagen breakdown
and synthesis are positioned at specific sites in human osteoarthritic
knee cartilage. Osteoarthritis Cartilage 2008, 16:615–623.
41. Charni-Ben TN, et al: The type II collagen fragments Helix-II and CTX-II
reveal different enzymatic pathways of human cartilage collagen
degradation. Osteoarthritis Cartilage 2008, 16:1183–1191.
42. Jensen LT: The aminoterminal propeptide of type III procollagen. Studies
on physiology and pathophysiology. Dan Med Bull 1997, 44:70–78.
43. Myllyla R, Becvar R, Adam M, Kivirikko KI: Markers of collagen metabolism
in sera of patients with various rheumatic diseases. Clin Chim Acta 1989,
183:243–252.
44. Hakala M, et al: Application of markers of collagen metabolism in serum
and synovial fluid for assessment of disease process in patients with
rheumatoid arthritis. Ann Rheum Dis 1995, 54:886–890.
45. Fueldner C, et al: Identification and evaluation of novel synovial tissue
biomarkers in rheumatoid arthritis by laser scanning cytometry. Arthritis
Res Ther 2012, 14:R8.
46. Syversen SW, et al: Biomarkers in early rheumatoid arthritis: longitudinal
associations with inflammation and joint destruction measured by
magnetic resonance imaging and conventional radiographs. Ann Rheum
Dis 2010, 69:845–850.
doi:10.1186/1479-5876-10-195
Cite this article as: Siebuhr et al.: Matrix Metalloproteinase-dependent
turnover of cartilage, synovial membrane, and connective tissue is
elevated in rats with collagen induced arthritis. Journal of Translational
Medicine 2012 10:195.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
